Loading...
•
Jun 30
Aclaris Therapeutics Q2 2025 Earnings Report
Aclaris Therapeutics reported Q2 2025 results with $1.78M revenue, higher R&D expenses from advancing multiple clinical programs, and a net loss of $15.43M.
Key Takeaways
Revenue was $1.78M, down from $2.77M YoY, driven by reduced licensing income. Net loss widened to $15.43M due to increased R&D spending on bosakitug and ATI-052 trials. Operating loss was $18.41M. Cash, cash equivalents, and marketable securities totaled $180.89M, providing runway into H2 2028.
Total revenue of $1.78M decreased from $2.77M in Q2 2024, primarily due to lower licensing income.
R&D expenses rose to $11.45M from $8.76M YoY, driven by clinical development of bosakitug and ATI-052.
Net loss increased to $15.43M, with EPS at -$0.13.
Cash position of $180.89M expected to fund operations into the second half of 2028.
Aclaris Therapeutics
Aclaris Therapeutics
Aclaris Therapeutics Revenue by Segment
Revenue by Segment
Contract research Revenue
CapyFin.comLicensing Revenue
CapyFin.com Forward Guidance
Aclaris expects its cash reserves to fund operations into H2 2028 while advancing bosakitug, ATI-2138, and ATI-052 through key clinical milestones.
Positive Outlook
- Strong cash runway expected to last into the second half of 2028.
- Advancing bosakitug into Phase 2 trial in atopic dermatitis with patient dosing underway.
- Positive Phase 2a results for ATI-2138 in moderate-to-severe AD, validating ITK as a target.
- Phase 1a/1b program for ATI-052 progressing with results expected in 2026.
- Exploring non-dilutive opportunities to extend cash runway.
Challenges Ahead
- Revenue declined YoY due to reduced licensing income.
- Higher R&D expenses driven by multiple ongoing trials.
- Net loss widened compared to prior year period.
- Exposure to clinical trial risks and uncertainties.
- Reliance on successful execution of development programs for future growth.